《復牌公告》創美藥業(02289.HK)9%股權轉手觸技術全購
創美藥業(02289.HK)公布,江西江中醫藥向控股股東兼主席姚創龍收購9%股權,涉及972萬股,總代價7,086萬元,相當於每股作價7.29元。完成後,買方及其一致行動人士於公司持股將由26.9%增至67.87%,須按例提出強制性全面要約,每股現金價7.29元,較停牌前收報折讓1.49%。
江中醫藥為江西省國有企業,主要開展藥品的批發和零售業務,以及食品、消毒設備和三類醫療器械的銷售業務。其擬維持公司的上市地位。
公司股份申請周四(29日)恢復買賣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.